Skip to content

Current addiction reports

ISSN 2196-2952

2 papers in the library · publishing 2025

Papers

The contribution of psychotherapy in potential therapeutic effects of psychedelics for treatment of opioid use disorder.

Current addiction reports January 1, 2025 Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.

A review of trials on psychedelics for opioid use disorder (OUD) found no studies directly comparing different types of psychotherapy or testing psychedelics with versus without concurrent psychotherapy. Most research on alleviating opioid withdrawal symptoms did not include psychotherapy. The few studies on ketamine and LSD for opioid use and abstinence used a psychedelic-assisted therapy model. There is insufficient high-quality evidence to determine whether concurrent psychotherapy is necessary in psychedelic trials for OUD. Future trials should explore the interplay between psychedelic treatment and psychotherapy.

An Update on the Epidemiology of Tusi ("Pink Cocaine").

Current addiction reports January 1, 2025 Nina Abukahok, Nicole D Fitzgerald, Joseph J Palamar

Tusi, or 'pink cocaine,' is a drug mixture containing ketamine and MDMA, often with additional substances like synthetic cathinones, cocaine, or methamphetamine. Its inconsistent chemical makeup complicates surveillance and harm reduction. Drug checking services have identified ketamine and MDMA as main components, with ketamine concentrations increasing over time in Spain. Surveys in Spain and Colombia show rising initiation, polysubstance use, and misclassification of tusi's contents. Harms stem largely from the polysubstance mixtures rather than any single component, yet mortality data typically focus on individual drugs. Tusi represents a novel trend: a blend of substances defined by its color and nightlife association, requiring standardized surveys, expanded drug checking, and improved toxicological monitoring.